The FDA approves Celgene's ([[CELG]] -0.8%) Otezla (apremilast) for the treatment of adult patients with oral ulcers associated Behçet’s Disease, a rare in
Zymeworks (ZYME) announces that collaboration partner Celgene (CELG) has selected a lead oncology candidate and has exercised its option for commercializat
(Bloomberg) -- Gilead Sciences Inc (NASDAQ:GILD). agreed to pay $5.1 billion to raise its stake in biotechnology company Galapagos NV to deepen its research into inflammatory...
UnitedHealth Group Inc.’s (NYSE:UNH) second-quarter 2019 earnings of $3.60 per share surpassed the Zacks Consensus Estimate by 4%. The same was up 15% year over year.Higher...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Strong Sell||Strong Sell||Strong Sell||Buy|
|Technical Indicators||BUY||Strong Sell||Strong Sell||Strong Sell||Strong Buy|
|Summary||Neutral||Strong Sell||Strong Sell||Strong Sell||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish Engulfing||1M||6||Jan 19|
|Three Inside Up||1H||9||Jul 18, 2019 01:00PM|
|Three Inside Up||1M||12||Jul 18|
|Bullish doji Star||1H||12||Jul 18, 2019 10:00AM|
|Tri-Star Bearish||15||12||Jul 19, 2019 12:45PM|
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.